Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (2134)
  2. Journal Article (1757)
  3. Review (262)
  4. Editorial (133)
  5. Research Letter (85)
  6. Correspondence (45)
  7. Book Section (31)
  8. Guidelines (25)
  9. Miscellaneous (14)
  10. Conference Paper (8)
Groups
  1. Department of Medicine (4175)
  2. Weinberg Fellows (2758)
  3. Hematologic Malignancies, Division of (2493)
  4. Solid Tumor Oncology Division (2424)
  5. Center for Hematologic Malignancies (1945)
  6. GSK Faculty (1879)

More Groups

People
  1. Sergio Giralt (433)
  2. Michael Scordo (389)
  3. Gunjan Shah (348)
  4. Miguel-Angel Perales (338)
  5. Sean Devlin (289)
  6. Marcel Van Den Brink (263)

More People

Years
  1. 2025 (346)
  2. 2024 (636)
  3. 2023 (600)
  4. 2022 (628)
  5. 2021 (503)
  6. 2020 (496)

More Years

Publications
  1. Blood (713)
  2. Journal of Clinical Oncology (685)
  3. Annals of Oncology (133)
  4. Clinical Cancer Research (131)
  5. Cancer Research (126)
  6. Biology of Blood and Marrow Transplantation (124)

More Publications

Publishers
  1. American Society of Hematology (806)
  2. American Society of Clinical Oncology (774)
  3. Elsevier Inc. (544)
  4. Nature Publishing Group (358)
  5. American Association for Cancer Research (352)
  6. Oxford University Press (211)

More Publishers

Results (4494)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization of actionable genetic alterations to guide targeted therapy for metastatic urothelial carcinoma
    Meeting Abstract

    Almassi, N.; Pietzak, E. J.; Funt, S. A.; Schultz, N.; Dalbagni, G.; Bochner, B. H.; Al-Ahmadie, H.; Bajorin, D. F.; Rosenberg, J. E.; Iyer, G.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes after cessation of therapy with alkylating agents (AA) for pancreatic neuroendocrine tumors (panNETs)
    Meeting Abstract

    Wu, L.; Reidy, D. L.; Bielska, A.; Kelly, V.; Raj, N. P.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone)
    Meeting Abstract

    Mulvey, C.; Raj, N. P.; Chan, J. A.; Aggarwal, R. R.; Cinar, P.; Hope, T. A.; Kolli, K.; Zhang, L.; Calabrese, S.; Grabowsky, J. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review
    Meeting Abstract

    Chan, D.; Bergsland, E. K.; Chan, J. A.; Gadgil, R.; Halfdanarson, T. R.; Hornbacker, K.; Kelly, V.; Kunz, P. L.; McGarrah, P. W.; Raj, N. P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Predictors of treatment response in colorectal high-grade neuroendocrine carcinomas (HGNEC): A single institution experience
    Meeting Abstract

    Corbett, V.; Raj, N. P.; Kelly, V.; Reidy, D. L.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial
    Meeting Abstract

    Won, H. H.; Selcuklu, S. D.; Piha-Paul, S. A.; Saura, C.; Rodon, J.; Mayer, I. A.; Loi, S.; Shapiro, G. I.; Lu, J.; Brufsky, A.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer
    Meeting Abstract

    Toska, E.; Xu, G.; Chhangawala, S.; Cocco, E.; Razavi, P.; Otto, J.; Cai, Y.; Chan, C.; D'Avino, D. R.; Collings, C.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Hyperactivation of mTORC1 drives acquired resistance to the pan -HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers
    Meeting Abstract

    Sudhan, D. R.; Guerrero-Zotano, A.; Won, H.; Ericsson, P. G.; Liu, Q.; Dugger, T.; Koch, J.; Schram, A.; Servetto, A.; Cutler, R.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Initial results from the phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors
    Meeting Abstract

    Schram, A.; Spreafico, A.; Oliva, M.; Brana, I.; Garralda, E.; Lakhani, N.; Von Hoff, D.; Borazanci, E.; Pandya, N.; Hoffman, K.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Prospective clinical sequencing distinguishes independent primary cancers from recurrent or metastatic disease
    Meeting Abstract

    Schram, A. M.; Bandlamudi, C.; Zehir, A.; Ladanyi, M.; Berger, M. F.; Taylor, B. S.; Hyman, D. M.
    Cancer Research (2019)

    Fulltext@MSK | Save